Literature DB >> 18701942

Medical management of irritable bowel syndrome in 2008: current and future directions.

Martin Storr1, Christopher N Andrews.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18701942      PMCID： PMC2661286          DOI： 10.1155/2008/145216

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN： 0835-7900            Impact factor:   3.522


× No keyword cloud information.
  18 in total

Review 1.  Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy.

Authors:  Michael Camilleri
Journal:  J Clin Gastroenterol       Date:  2006-03       Impact factor: 3.062

2.  A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children.

Authors:  A Gawrońska; P Dziechciarz; A Horvath; H Szajewska
Journal:  Aliment Pharmacol Ther       Date:  2007-01-15       Impact factor: 8.171

Review 3.  IBS--review and what's new.

Authors:  Amy Foxx-Orenstein
Journal:  MedGenMed       Date:  2006-07-26

4.  Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.

Authors:  Viola Andresen; Michael Camilleri; Irene A Busciglio; April Grudell; Duane Burton; Sanna McKinzie; Amy Foxx-Orenstein; Caroline B Kurtz; Vineeta Sharma; Jeffrey M Johnston; Mark G Currie; Alan R Zinsmeister
Journal:  Gastroenterology       Date:  2007-07-03       Impact factor: 22.682

5.  Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome.

Authors:  Lawrence A Szarka; Michael Camilleri; Duane Burton; Jean C Fox; Sanna McKinzie; Timothy Stanislav; Julie Simonson; Nancy Sullivan; Alan R Zinsmeister
Journal:  Clin Gastroenterol Hepatol       Date:  2007-09-27       Impact factor: 11.382

6.  How does cognitive behavior therapy for irritable bowel syndrome work? A mediational analysis of a randomized clinical trial.

Authors:  Jeffrey M Lackner; James Jaccard; Susan S Krasner; Leonard A Katz; Gregory D Gudleski; Edward B Blanchard
Journal:  Gastroenterology       Date:  2007-05-21       Impact factor: 22.682

7.  Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome.

Authors:  L A Houghton; C Fell; P J Whorwell; I Jones; D P Sudworth; J D Gale
Journal:  Gut       Date:  2007-04-19       Impact factor: 23.059

Review 8.  Drug evaluation: Pumosetrag for the treatment of irritable bowel syndrome and gastroesophageal reflux disease.

Authors:  Stefano Evangelista
Journal:  Curr Opin Investig Drugs       Date:  2007-05

9.  A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.

Authors:  Richard Krause; Vanessa Ameen; Susan H Gordon; Marquita West; Amy T Heath; Teresa Perschy; Eric G Carter
Journal:  Am J Gastroenterol       Date:  2007-05-17       Impact factor: 10.864

10.  Low-dose naltreoxone for the treatment of irritable bowel syndrome: a pilot study.

Authors:  Revital Kariv; Elisa Tiomny; Roman Grenshpon; Roy Dekel; Galit Waisman; Yehuda Ringel; Zamir Halpern
Journal:  Dig Dis Sci       Date:  2006-11-01       Impact factor: 3.487
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.